A detailed history of Gts Securities LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Gts Securities LLC holds 47,000 shares of EXEL stock, worth $1.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
47,000
Previous 43,300 8.55%
Holding current value
$1.56 Million
Previous $972,000 25.41%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$20.34 - $23.73 $189,772 - $221,400
-9,330 Reduced 43.64%
12,048 $270,000
Q1 2024

May 15, 2024

SELL
$20.17 - $23.93 $4.09 Million - $4.86 Million
-202,910 Reduced 90.47%
21,378 $507,000
Q4 2023

Feb 14, 2024

SELL
$19.25 - $24.13 $61,792 - $77,457
-3,210 Reduced 1.41%
224,288 $5.38 Million
Q3 2023

Nov 15, 2023

BUY
$19.04 - $22.74 $2.09 Million - $2.5 Million
109,741 Added 93.19%
227,498 $4.97 Million
Q2 2023

Aug 15, 2023

BUY
$18.17 - $20.48 $2.14 Million - $2.41 Million
117,757 New
117,757 $2.25 Billion

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.